Safety and Immunogenicity of the rVSV ΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Years and in Their Adults and/or Children Relatives Living in Lambaréné, Gabon
Condition: Ebola Virus Disease Intervention: Biological: rVSVΔG-ZEBOV-GP, V920 Sponsors: Centre de Recherche Médicale de Lambaréné; Merck Sharp & Dohme Corp. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 23, 2021 Category: Research Source Type: clinical trials
International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)
Condition: COVID-19 Intervention: Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo; Partnership for Clinical Research in Guinea/Partenariat de Recherche Clinique en Guinée (PREGUI); National Institute of Health Resea rch and Development, Ministry of Health Republic of Indonesia; Partnership for Research on Ebola Virus in Liberia (PREVAIL); University Clinical Research Center, Mali; National Institute of Medical Sciences and Nutrition, Salvador Zubiran Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2021 Category: Research Source Type: clinical trials
